-
ATRX Loss Heightens Glioma Sensitivity to PDGFR Inhibition
2026-06-24
Pladevall-Morera et al. revealed that ATRX-deficient high-grade glioma cells are unusually sensitive to RTK and selective PDGFRα/β inhibitors. This finding suggests ATRX status should inform therapeutic strategies in glioblastoma and may optimize the use of PDGFR inhibitors in cancer research.
-
PD 173074 in Diabetic Kidney Disease: FGFR1 Inhibition Beyon
2026-06-23
Explore how PD 173074, a selective FGFR1 inhibitor, advances research in diabetic kidney disease by targeting podocyte survival and glomerular function. This article examines its mechanistic impact and protocol guidance, setting it apart from oncology-centric content.
-
Foretinib (GSK1363089): Applied Workflows for Tumor Growth I
2026-06-23
Foretinib (GSK1363089) stands out as a precision multikinase inhibitor for dissecting tumor growth and metastasis mechanisms in both in vitro and in vivo cancer models. This guide translates advanced research protocols and troubleshooting strategies into practical, reproducible workflows for maximizing the impact of Foretinib in your oncology studies.
-
Foretinib (GSK1363089) in Multikinase Cancer Models: Protoco
2026-06-22
Foretinib (GSK1363089) empowers precise tumor cell growth inhibition and metastasis modeling through robust, multikinase targeting. This article delivers actionable protocols, troubleshooting tips, and workflow enhancements, building on advanced in vitro metrics and the latest translational oncology research.
-
EGTA (Egtazic Acid): Precision Calcium Modulation in Researc
2026-06-22
EGTA (egtazic acid) empowers researchers to dissect calcium-dependent mechanisms with unrivaled selectivity, enabling robust neuroprotection and cardiac signaling assays. This article demystifies EGTA’s applied benefits, experimental workflows, and troubleshooting strategies, connecting bench protocols to translational outcomes.
-
Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod
2026-06-21
This study introduces a novel patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations. The innovation enables detailed investigation of tumor-stroma interactions, gene expression, and drug response, representing a major advance for personalized cancer biology research and preclinical drug testing.
-
FLT3–TAZ Signaling and TKI Resistance in Blast Phase CML
2026-06-20
Shin et al. reposition FLT3 as a key prognostic marker and actionable target in blast phase chronic myeloid leukemia (BP-CML), demonstrating that FLT3–TAZ pathway activation drives resistance to BCR::ABL1 tyrosine kinase inhibitors (TKIs) independent of mutation status. Their integrative multi-omics and translational approach suggests that targeting FLT3, alone or in combination therapies, may overcome resistance and improve outcomes in BP-CML.
-
Disulfiram: Proteasome Inhibitor for Cancer Research Workflo
2026-06-19
Disulfiram’s dual role as a dopamine β-hydroxylase inhibitor and a copper-complex proteasome inhibitor positions it as a powerful tool for precision cancer research. This guide translates recent synthetic lethality findings and hands-on workflow tips into actionable protocols, helping scientists maximize reproducibility and experimental clarity.
-
PP2A-Driven Autophagy and Drug Resistance in Candida albican
2026-06-19
This study reveals that protein phosphatase 2A (PP2A) modulates drug resistance in Candida albicans biofilms by regulating autophagy through ATG protein phosphorylation. These findings clarify a mechanistic link between autophagy, biofilm formation, and antifungal resistance, offering a foundation for targeted strategies in candidiasis research and therapy.
-
CBD Attenuates Orofacial Inflammatory Pain via Multi-Level M
2026-06-18
This study establishes cannabidiol's efficacy in reducing both sensory and affective components of orofacial inflammatory pain in mice. By dissecting peripheral and central molecular pathways, the research provides translational insights for comprehensive pain management strategies targeting inflammation-induced pain and its emotional comorbidities.
-
CDC42 Modulates HBV Entry via NTCP Trafficking and Macropino
2026-06-18
This study uncovers how CDC42, a Rho GTPase, facilitates hepatitis B virus (HBV) entry by promoting NTCP translocation to the plasma membrane and enabling macropinocytosis. The findings reveal an unrecognized mechanism for HBV internalization, suggesting new antiviral intervention points in host trafficking pathways.
-
Plerixafor (AMD3100): Protocols and Innovations in CXCR4 Res
2026-06-17
Plerixafor (AMD3100) unlocks precision targeting of the CXCR4/CXCL12 axis, enabling robust workflows for cancer metastasis inhibition and stem cell mobilization. This guide distills actionable experimental steps, troubleshooting insights, and the latest comparative findings to maximize research impact.
-
PD0325901 MEK Inhibitor: Protocols and Innovations in Cancer
2026-06-17
PD0325901 is redefining MEK pathway research, enabling precise cell cycle and apoptosis studies in cancer and developmental biology. This guide delivers actionable workflows, experimental enhancements, and troubleshooting insights grounded in the latest mechanistic findings.
-
Patient-Derived Gastric Cancer Assembloids Reveal Stromal Mo
2026-06-16
This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and autologous stromal cell subpopulations, faithfully replicating the cellular heterogeneity and tumor microenvironment seen in vivo. The model uncovers how stromal components significantly alter gene expression and drug sensitivity, providing a robust system for dissecting resistance mechanisms and advancing personalized cancer research.
-
Patient-Derived Gastric Cancer Assembloids: Modeling Tumor–S
2026-06-16
This paper introduces a patient-derived gastric cancer assembloid model that co-cultures matched tumor organoids and stromal cell subpopulations, better reflecting the cellular heterogeneity and microenvironment of primary tumors. The approach enables nuanced study of drug responses and resistance mechanisms, supporting the development of more effective personalized therapies.